A SHAREHOLDERS' AGREEMENT BETWEEN INVESTORS AND SPECIALISED FUNDS

MEDSENIC accelerates its development and opens its capital to investment players with a fund raising from two French players, Capital Grand Est (Cap Innov'Est) and Fa Dièse (Fa Dièse 3). The CNRS, through its subsidiary Fist SA, also becomes a shareholder of the company. New private investors have also contributed to this capital increase, MEDSENIC still being significantly supported by its historical investors.

This equity investment allows the company to conduct the GvHD clinical trial under optimal conditions, while serenely building future developments to make Medsenic an undisputed leader in the market for autoimmune orphan diseases.

Today, MEDSENIC is formalizing its valuation and is stepping up its search for partners, whether leading pharmaceutical companies or specialized investment funds, to create strategic alliances and licensing agreements.